Literature DB >> 34363496

The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis.

Sofia Tsiapakidou1, Apostolos Apostolidis2, Konstantinos Pantazis3, Grigoris F Grimbizis1, Themistoklis Mikos4.   

Abstract

INTRODUCTION AND HYPOTHESIS: Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and other proteins are related to overactive bladder (OAB) syndrome, as their urinary concentrations are significantly different from those of the general non-OAB population. This review aims to systematically assess whether NGF, BDNF, and other urinary by-products can be used as potential biomarkers to manage women with OAB.
METHODS: This was a systematic review and metanalysis that was conducted according to PRISMA guidelines. Studies were identified by electronic search of Medline, Scopus, ScienceDirect, Embase, and Cochrane Register until October 2020. The included studies investigated the correlation of OAB with NGF, BDNF, and other potential biomarkers in symptomatic women and their controls.
RESULTS: Twelve studies (581 female OAB patients and 394 female controls) were included. Urinary NGF, NGF/Cr, BDNF/Cr, ATP/Cr, and PGE2/Cr ratios were identified as potential biomarkers in female OAB patients. Results of the meta-analysis indicated that uNGF [standard mean difference (SMD) 1.45, 95% CI 0.53-2.36], NGF/Cr ratio (SMD 1.23, 95% CI 0.67-1.78), BDNF/Cr ratio (SMD 0.78, 95% CI 0.006-1.50), and BDNF/Cr ratio (RR 0.78, 95% CI 0.006-1.50) were increased in female OAB patients compared to healthy controls, whereas no difference was found for the PGE2/Cr and ATP/Cr ratios. Current data are inadequate to assess any other potential biomarkers, such as urinary MDA, ATP, and cytokines, in the management of OAB in female patients.
CONCLUSIONS: uNGF, NGF/Cr, and BDNF/Cr ratio could be used in the assessment of female OAB patients. Further studies are needed to specify OAB urinary titer levels in OAB subgroups and healthy women and their potential as diagnostic and management tools in OAB women.
© 2021. The International Urogynecological Association.

Entities:  

Keywords:  BDNF; Biomarker; Brain-derived neurotrophic factor; NGF; Nerve growth factor; OAB; Overactive bladder

Mesh:

Substances:

Year:  2021        PMID: 34363496     DOI: 10.1007/s00192-021-04945-1

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  40 in total

Review 1.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

2.  An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) & grafts in female pelvic floor surgery.

Authors:  Bernard T Haylen; Robert M Freeman; Steven E Swift; Michel Cosson; G Willy Davila; Jan Deprest; Peter L Dwyer; Brigitte Fatton; Ervin Kocjancic; Joseph Lee; Chris Maher; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer; Ralph J Webb
Journal:  Int Urogynecol J       Date:  2011-01       Impact factor: 2.894

Review 3.  What are biomarkers?

Authors:  Kyle Strimbu; Jorge A Tavel
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

4.  Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder.

Authors:  G Vijaya; R Cartwright; A Derpapas; P Gallo; R Fernando; V Khullar
Journal:  Int Urogynecol J       Date:  2013-02-02       Impact factor: 2.894

Review 5.  Neurotrophins in bladder function: what do we know and where do we go from here?

Authors:  Célia Duarte Cruz
Journal:  Neurourol Urodyn       Date:  2013-06-17       Impact factor: 2.696

6.  Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder.

Authors:  Long-Wang Wang; Xiao-Min Han; Chao-Hui Chen; Yan Ma; Bo Hai
Journal:  Int Urol Nephrol       Date:  2013-08-28       Impact factor: 2.370

7.  Urinary neurotrophic factors in healthy individuals and patients with overactive bladder.

Authors:  Tiago Antunes-Lopes; Rui Pinto; Sérgio C Barros; Francisco Botelho; Carlos M Silva; Célia D Cruz; Francisco Cruz
Journal:  J Urol       Date:  2012-11-19       Impact factor: 7.450

8.  Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome.

Authors:  Hann-Chorng Kuo
Journal:  Low Urin Tract Symptoms       Date:  2012-03       Impact factor: 1.592

9.  Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013.

Authors:  Marcus J Drake
Journal:  Neurourol Urodyn       Date:  2014-05-16       Impact factor: 2.696

Review 10.  Biomarkers in overactive bladder.

Authors:  Alka A Bhide; Rufus Cartwright; Vik Khullar; G Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2013-01-12       Impact factor: 2.894

View more
  1 in total

1.  Does COVID-19 Vaccination Cause Storage Lower Urinary Tract Symptoms?

Authors:  Yu-Chen Chen; Yin-Chi Liang; Shuo-Jung Ho; Hao-Wei Chen; Yung-Shun Juan; Wei-Chung Tsai; Shu-Pin Huang; Jung-Ting Lee; Yu-Peng Liu; Chung-Yao Kao; Yen-Ko Lin; Cheng-Yu Long; Meng-Ni Wu; Chao-Ju Chen; Wen-Jeng Wu
Journal:  J Clin Med       Date:  2022-05-12       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.